Case Study

Opioid use disorder

Medication-assisted treatment (MAT) can be delivered with take-home buprenorphine, but research suggests only 20 percent of patients with an opioid use disorder receive any treatment. Concerns about adherence is one barrier to prescribing buprenorphine.

Solution: emocha’s HIPAA-compliant mobile technology provides dose-by-dose adherence verification and tools for patient engagement. Our platform gives providers the assurance that their patients are supported and successful in treatment and notifies them when patients need additional assistance.

Opioid treatment programs like Pathway Healthcare leverage emocha at clinics across the country.

Case Study


DOT is the standard of care for tuberculosis (TB) treatment, but it can be costly and time-consuming. Infectious Diseases Society of America guidelines acknowledge video DOT as an alternative to in-person DOT that can support health departments facing staffing shortages and budget limitations.

Solution: Secure, asynchronous video DOT allows patients and providers to complete DOT on their own schedule, dramatically reducing the cost of travel for providers and minimizing the impact on patient’s lives.

Harris County, Texas has used emocha for active and latent TB treatment with over 400 patients since 2014.

Download our Fresno County case study.

Case Study

Hepatitis C Virus

For a standard 12-week regimen, hepatitis C (HCV) medications can cost upwards of $40,000. One in four patients is denied coverage upon initial request if they are expected to be nonadherent.

Solution: Verified records of adherence can help reduce the barriers patients face to prior authorization and give providers the confidence to prescribe treatment.

Massachusetts General Hospital, Harvard Medical School’s largest teaching hospital, is one of the leading academic medical centers using emocha to support people who inject drugs and are receiving HCV treatment.

Case Study


The World Health Organization (WHO) has made it a priority to identify strategies that improve antiretroviral treatment adherence and long-term care retention for people with HIV. Similarly, the U.S. Centers for Disease Control and Prevention have made significant investments to connect individuals to Pre-exposure Prophylaxis, known as PrEP, for HIV prevention.

Solution: Health coaches in three cities use emocha to link patients to care and provide support during vulnerable times. According to the NIH, the savings would reach $338,400 per patient if all HIV-infected individuals presented early and remained in care, staying adherent to their medication. (Source)

In Baltimore City, Philadelphia, and Washington, D.C., health coaches have used emocha to link hundreds of patients to treatment for HIV and PrEP.